Ovarian carcinoma: Adjuvant treatment with P-32

S. Reddy, G. P. Sutton, F. B. Stehman, N. B. Hornback, C. E. Ehrlich

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Twenty-eight patients with ovarian carcinoma received 555 MBq of labeled chromic phosphate (P-32) intraperitoneally. Indications for treatment included a high-grade tumor, extracapsular involvement, positive cytologic findings, or residual tumor. Fifteen patients (group 1) had stage I, II, or III completely resected tumor; 13 patients (group 2) had microscopic or less than 3-mm lesions at second-look laparotomy following combination chemotherapy. A major complication occurred in one patient; two patients had minor complications. Overall, 24 of 28 patients (85.7%) were alive at 11-77 months; 23 (82.1%) had no evidence of tumor. Fifteen of 15 (100%) group 1 patients and eight of 13 (61.5%) group 2 patients did not have tumor relapse after 30 months and 28 1/2 months, respectively. P-32 was found to be an effective adjuvant treatment in a select group of patients with ovarian carcinoma who were at high risk for intraabdominal recurrence.

Original languageEnglish (US)
Pages (from-to)275-278
Number of pages4
Issue number1
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Ovarian carcinoma: Adjuvant treatment with P-32'. Together they form a unique fingerprint.

Cite this